نتائج البحث - J.R. Germà

  • يعرض 1 - 13 نتائج من 13
تنقيح النتائج
  1. 1
    Tumour-marker levels and prognosis in malignant teratoma of the testis

    Tumour-marker levels and prognosis in malignant teratoma of the testis حسب J. R. Germa-Lluch, Richard H. J. Beǵent, K. D. Bagshawe

    منشور في 1980
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    The PDGFRβ–AKT Pathway Contributes to CDDP-Acquired Resistance in Testicular Germ Cell Tumors

    The PDGFRβ–AKT Pathway Contributes to CDDP-Acquired Resistance in Testicular Germ Cell Tumors حسب M. Juliachs, C. Muñoz, Cátia Moutinho, August Vidal, Enric Condom, Manel Esteller, Mariona Graupera, Oriol Casanovas, J.R. Germà, Alberto Villanueva, Francesc Viñals

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)

    A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis ge... حسب Gedske Daugaard, Iwona Skoneczna, Nina Aass, Ronald de Wit, Maria De Santis, Herlinde Dumez, Sandrine Marréaud, Laurence Collette, J. R. Germá Lluch, Carsten Bokemeyer, Hans‐Joachim Schmoll

    منشور في 2010
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Randomized Phase III Study Comparing Paclitaxel–Bleomycin, Etoposide, and Cisplatin (BEP) to Standard BEP in Intermediate-Prognosis Germ-Cell Cancer: Intergroup Study EORTC 30983

    Randomized Phase III Study Comparing Paclitaxel–Bleomycin, Etoposide, and Cisplatin (BEP) to Standard BEP in Intermediate-Prognosis Germ-Cell Cancer: Intergroup Study EORTC 30983 حسب Ronald de Wit, Iwona Skoneczna, Gedske Daugaard, Maria De Santis, August Garin, Nina Aass, Alfred Witjes, Peter Albers, J.D. White, J. R. Germa-Lluch, Sandrine Marréaud, Laurence Collette

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database

    Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database حسب Anja Lorch, Caroline Mollévi, Andrew Kramar, Lawrence Einhorn, Andrea Necchi, Christophe Massard, Ugo De Giorgi, Aude Fléchon, Kim Margolin, Jean-Pierre Lotz, J. R. Germa-Lluch, Thomas Powles, Christian Kollmannsberger, J. Beyer

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma

    Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma حسب Jorge Aparicio, Xavier García del Muro, Pablo Maroto, Luis Paz‐Ares, Emilio Alba, A. Sáenz, Josefa Terrasa, Agustí Barnadas, D. Almenar, José Ángel Arranz, Miguel A. Sánchez, António Fernández, Javier Sastre, Joan Carles, Joan Dorca, Josep Gumà, A. Yuste, J.R. Germá

    منشور في 2003
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Risk-Adapted Treatment in Clinical Stage I Testicular Seminoma: The Third Spanish Germ Cell Cancer Group Study

    Risk-Adapted Treatment in Clinical Stage I Testicular Seminoma: The Third Spanish Germ Cell Cancer Group Study حسب Jorge Aparicio, Pablo Maroto, Xavier García del Muro, Josep Gumà, Alfonso Sánchez‐Muñoz, Mireia Margelí Vila, Montserrat Domènech, R. Bastús, António Fernández, M. López-Brea, J. Terrassa, Andrés Meana, Purificación Martínez del Prado, Javier Sastre, Juan J. Satrústegui, Regina Gironés, Lídia Robert, J.R. Germá

    منشور في 2011
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)

    Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG) حسب Jorge Aparicio, Pablo Maroto, Xavier García del Muro, Alfonso Sánchez‐Muñoz, Josep Gumà, Mireia Margelí Vila, A. Sáenz, N. Sagastibelza, Daniel Castellano, José Ángel Arranz, David Hervás, R. Bastús, António Fernández, Javier Sastre, Josefa Terrasa, M. López-Brea, Joan Dorca, D. Almenar, Joan Carles, Amaia Hernández, J.R. Germá

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Risk-Adapted Management for Patients With Clinical Stage I Seminoma: The Second Spanish Germ Cell Cancer Cooperative Group Study

    Risk-Adapted Management for Patients With Clinical Stage I Seminoma: The Second Spanish Germ Cell Cancer Cooperative Group Study حسب Jorge Aparicio, J.R. Germá, Xavier García del Muro, Pablo Maroto, José Ángel Arranz, A. Sáenz, Agustín Barnadas, Joan Dorca, Josep Gumá, David Olmos, R. Bastús, Joan Carles, D. Almenar, M.A. Sánchez-Granero, Luis Paz‐Ares, Juan J. Satrústegui, Begoña Mellado, A. Balil, M. López-Brea, Alfredo Sánchez

    منشور في 2005
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer

    Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer حسب Jan Oldenburg, Jorge Aparicio, J. Beyer, Gabriella Cohn‐Cedermark, M.H. Cullen, Timothy D. Gilligan, Ugo De Giorgi, Maria De Santis, Ronald de Wit, S. D. Fosså, J. R. Germa-Lluch, Silke Gillessen, Hege Sagstuen Haugnes, Friedemann Honecker, A. Horwich, Anja Lorch, D Ondruš, Giovanni Rosti, Andrew J. Stephenson, Torgrim Tandstad

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel

    Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel حسب Paul Hoskins, Ignace Vergote, Andrés Cervantes, Dongsheng Tu, Gavin Stuart, Paolo Zola, A. Poveda, Diane Provencher, Dionyssios Katsaros, B. Ojeda, Prafull Ghatage, Robert Grimshaw, Antonio Casado, Laurie Elit, C. Mendiola, Akira Sugimoto, Véronique D’Hondt, Amit M. Oza, J. R. Germa, Manas Pratim Roy, Lori A. Brotto, D. Chen, Elizabeth A. Eisenhauer

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up

    ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up حسب Friedemann Honecker, Jorge Aparicio, Daniel M. Berney, J. Beyer, Carsten Bokemeyer, Richard Cathomas, Noel W. Clarke, Gabriella Cohn‐Cedermark, Gedske Daugaard, K.-P. Dieckmann, Karim Fizazi, Sophie D. Fosså, J. R. Germa-Lluch, Patrizia Giannatempo, Jourik A. Gietema, Silke Gillessen, Hege Sagstuen Haugnes, Axel Heidenreich, Kari Hemminki, Robert Huddart, Michael A.S. Jewett, Florence Joly, Jakob Lauritsen, Anja Lorch, Andrea Necchi, Nicola Nicolai, Christoph Oing, Jan Oldenburg, D Ondruš, Alexandros Papachristofilou, Thomas Powles, Aslam Sohaib, O. Ståhl, Torgrim Tandstad, Guy C. Toner, A. Horwich

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer

    Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer حسب J. Beyer, Peter Albers, Renske Altena, Jorge Aparicio, Carsten Bokemeyer, Jonas Busch, Richard Cathomas, Eva Cavallin‐Ståhl, Noel W. Clarke, Joseph Claßen, Gabriella Cohn‐Cedermark, Alv A. Dahl, Gedske Daugaard, Ugo De Giorgi, Maria De Santis, Maike de Wit, Ronald de Wit, K.-P. Dieckmann, Martin Fenner, Karim Fizazi, Aude Fléchon, Sophie D. Fosså, J. R. Germá Lluch, Jourik A. Gietema, Silke Gillessen, A. Giwercman, J.T. Hartmann, Axel Heidenreich, Marcus Hentrich, Friedemann Honecker, A. Horwich, Robert Huddart, Sabine Kliesch, Christian Kollmannsberger, S. Krege, M. Pilar Laguna, Leendert H. J. Looijenga, Anja Lorch, Jean‐Pierre Lotz, Frank Mayer, Andrea Necchi, Nicola Nicolai, Janine Nuver, Karin Oechsle, Jan Oldenburg, J. Wolter Oosterhuis, Tom Powles, Ewa Rajpert‐De Meyts, Oliver Rick, Giovanni Rosti, Roberto Salvioni, M. Schrader, Stefan Schweyer, Felix Sedlmayer, Aslam Sohaib, Rainer Souchon, Torgrim Tandstad, Christian Winter, Christian Wittekind

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: